Redeye: Iconovo Q4 - Waiting for an ICOpre deal
Redeye provides an update following Iconovo’s Q4 2024 report. The report was relatively undramatic overall; however, we have mixed feelings regarding an ICOpre deal, which is vital for the company and our investment case. We make some model adjustments based on the report; however, our fair value range remains untouched.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/